The incretin-based peptide research landscape has expanded rapidly in recent years, progressing from single-receptor GLP-1 agonists to multi-receptor compounds that engage two or three metabolic signaling pathways simultaneously. Three compounds now define the core of this field: semaglutide, tirzepatide, and retatrutide.
Access verified quality documentation and research-grade peptides.
View Certificates of Analysis Explore Research-Grade PeptidesDisclaimer: All compounds referenced in this article are intended for laboratory research use only. They are not approved for human or veterinary use by the FDA or any regulatory agency.